Massachusetts 2025-2026 Regular Session

Massachusetts Senate Bill S817

Introduced
2/27/25  
Refer
2/27/25  
Refer
12/4/25  

Caption

To ensure access to epinephrine for minors

Impact

If enacted, S817 would significantly impact healthcare access for minors suffering from severe allergies by ensuring that their families can obtain epinephrine injectors without financial barriers. This includes eliminating deductibles, co-insurance, and co-payments for these injectors, which should help alleviate the financial burden on families and promote better health outcomes for children who may otherwise experience life-threatening allergic reactions. The expansion of insurance coverage to include these critical medical devices could also encourage more parents to pursue necessary allergy testing and treatment.

Summary

Senate Bill S817, titled 'An Act to ensure access to epinephrine for minors', aims to mandate coverage for medically necessary epinephrine injectors for individuals under the age of 18. The bill proposes amendments to several chapters of the General Laws of Massachusetts, specifically outlining that both public and private insurers must provide coverage for epinephrine injectors without cost-sharing for minors. This would encompass auto-injectors and pre-filled syringes that are FDA-approved, ensuring that caregivers and guardians have appropriate access to essential medical supplies for children at risk of severe allergic reactions.

Contention

Some points of contention surrounding S817 may stem from concerns about the costs to insurers and how they might pass some of these costs onto other consumers in the health insurance market. Stakeholders from insurers or health plans may raise discussions regarding the potential for premium increases following the implementation of the bill. Additionally, while the bill is primarily focused on enhancing health outcomes for minors, discussions may arise regarding the need for similar provisions for adults or the broader implications for public health policy related to allergy management.

Companion Bills

No companion bills found.

Previously Filed As

MA H2500

Relative to increasing access to epinephrine

MA H4607

Relative to increasing access to epinephrine

MA H1206

Relative to epinephrine injectors

MA SF2690

Requirements modification for access to epinephrine in schools

MA H4943

Relative to epinephrine injectors

MA H611

Relative to emergency stock epinephrine in schools

MA HF2489

Epinephrine access in schools requirements modified.

MA H1284

Ensuring banking accessibility

MA A3655

Extends "Epinephrine Access and Emergency Treatment Act" to include administration of epinephrine auto-injector devices by individuals in possession of devices pursuant to personal prescriptions.

MA S1610

Assessing healthcare access

Similar Bills

TX SB1619

Relating to the use of an epinephrine delivery system by certain entities.

TX HB2283

Relating to the use of an epinephrine delivery device by certain entities.

NH HB63

Relative to the use of nasal spray to treat anaphylaxis.

NH HB677

Relative to the possession and use of epinephrine at recreation camps, schools, and institutions of higher education.

MA H1206

Relative to epinephrine injectors

MA H4943

Relative to epinephrine injectors

TX SB1374

Relating to the administration of epinephrine medication by public and private schools.

TX HB2801

Relating to the definition of an epinephrine delivery device and the use of those devices in public and private schools.